Wednesday, February 20, 2013- Merck's Low Cholesterolat Motley Fool (Wed, Feb 20)
- Agilent Unit Receives FDA ApprovalZacks (Wed, Feb 20)
- Studies Examine Novel Use For New Oral Anticoagulant Drugsat Forbes (Wed, Feb 20)
- Has Johnson & Johnson Become the Perfect Stock?at Motley Fool (Wed, Feb 20)
- GSK's HIV Drug Gets Priority ReviewZacks (Wed, Feb 20)
- Launch at Novo NordiskZacks (Wed, Feb 20)
- 4 Ways to Play Our Love for Man's Best Friendat Motley Fool (Wed, Feb 20)
- March Action Date for UTHR CandidateZacks (Wed, Feb 20)
- Which of These Top 5 Pharma Stocks Have the Strongest Earnings Trends?at Wall St. Cheat Sheet (Wed, Feb 20)
- Is Eli Lilly Being Wise About YZ?at Motley Fool (Wed, Feb 20)
- 5 Health Care Stocks Triggering 'Buys' This Weekat TheStreet (Wed, Feb 20)
Tuesday, February 19, 2013- BioMarin Earnings: An Early Lookat Motley Fool (Tue, Feb 19)
- Will Isis Right Pfizer's Wrong?at Motley Fool (Tue, Feb 19)
- Novartis' Exorbitant Pay Package For Former CEO Was More Ridiculous Than It Lookedat Forbes (Tue, Feb 19)
- SAC’s Cohen May Face SEC Suit as Deposition Hurts Caseat Bloomberg (Tue, Feb 19)
- Pfizer Inc (PFE): Today's Featured Drugs Winnerat TheStreet (Tue, Feb 19)
- ACT Biotech co-founder Ali Fattaey makes tracks to Curisat bizjournals.com (Tue, Feb 19)
- 3 Foolish Reasons to Buy This Expensive Stockat Motley Fool (Tue, Feb 19)
- P&G Affected by Currency Devaluation and 3 Heavily Traded Shares Moving Nowat Wall St. Cheat Sheet (Tue, Feb 19)
- Actavis Beats on EarningsZacks (Tue, Feb 19)
- Drugmaker Actavis' 4Q earnings sink 70 percentAP (Tue, Feb 19)
- Huge Upside Potential Despite Recent Ralliesat Motley Fool (Tue, Feb 19)
- [video] FMHR Final Tradeat CNBC (Tue, Feb 19)
- The Sum of Its Parts: Consumer Productsat Motley Fool (Tue, Feb 19)
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ConferenceBusiness Wire (Tue, Feb 19)
Add PFE News to My Yahoo!   | |
|
0.29(0.99%) May 17, 4:00PM EDT|After Hours
:
28.99